Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial-Reference-Cited by-同舟云学术

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Published:2019-07 Issue:7 Volume:20 Page:948-960
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Rozeman Elisa A,Menzies Alexander M,van Akkooi Alexander C J,Adhikari Chandra,Bierman Carolien,van de Wiel Bart A,Scolyer Richard A,Krijgsman Oscar,Sikorska Karolina,Eriksson Hanna,Broeks Annegien,van Thienen Johannes V,Guminski Alexander D,Acosta Alex Torres,ter Meulen Sylvia,Koenen Anne Miek,Bosch Linda J W,Shannon Kerwin,Pronk Loes M,Gonzalez Maria,Ch'ng Sydney,Grijpink-Ongering Lindsay G,Stretch Jonathan,Heijmink Stijn,van Tinteren Harm,Haanen John B A G,Nieweg Omgo E,Klop Willem M C,Zuur Charlotte L,Saw Robyn P M,van Houdt Winan J,Peeper Daniel S,Spillane Andrew J,Hansson Johan,Schumacher Ton N,Long Georgina V,Blank Christian U

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual;Gershenwald;CA Cancer J Clin,2017

2. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial;Henderson;Lancet Oncol,2015

3. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy;Eggermont;N Engl J Med,2016

4. Adjuvant pembrolizumab versus placebo in resected stage III melanoma;Eggermont;N Engl J Med,2018

5. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma;Weber;N Engl J Med,2017

Cited by 324 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global research trends in tongue cancer from 2000 to 2022: bibliometric and visualized analysis;Clinical Oral Investigations;2024-02-02

2. Perioperative therapy of melanoma: Adjuvant or neoadjuvant treatment;European Journal of Surgical Oncology;2024-02

3. Adjuvant Systemic Therapy in Melanoma: Relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)?;EJC Skin Cancer;2024-02

4. Neoadjuvant therapy for resectable melanoma;Clinical & Experimental Metastasis;2024-01-28

5. Neoadjuvant personalized cancer vaccines: the final frontier?;Expert Review of Vaccines;2024-01-10